AZD4547

DRUG12 trials

Sponsors

AstraZeneca, ECOG-ACRIN Cancer Research Group, UNICANCER, University of Birmingham, Assistance Publique - Hôpitaux de Paris

Conditions

AdenocarcinomaAdvanced Solid MalignanciesCancerCarcinoma, Squamous CellER+ Breast CancerFGFR Inhibition, Pharmacokinetics, BiomarkersGastric CancerGastro-oesophageal Junction Cancer

Phase 1

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

TerminatedNCT00979134

AstraZenecaAdvanced Solid Malignancies, Cancer

Start: 2009-10-21End: 2015-03-05Updated: 2019-03-15

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

CompletedNCT01202591

AstraZenecaER+ Breast Cancer, FGFR Inhibition, Pharmacokinetics, Biomarkers

Start: 2010-12-31End: 2014-10-31Updated: 2016-02-11

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

CompletedNCT01213160

AstraZenecaAdvanced Solid Malignancies, Cancer

Start: 2010-11-30End: 2013-06-30Updated: 2016-06-29

Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer

CompletedNCT01824901

ECOG-ACRIN Cancer Research GroupRecurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer

Start: 2014-01-15End: 2015-04-30Updated: 2023-06-29

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Active, not recruitingNCT02546661

AstraZenecaMuscle Invasive Bladder Cancer

Start: 2016-12-28End: 2026-01-30Updated: 2025-12-29

Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion

CompletedNCT02824133

Assistance Publique - Hôpitaux de ParisRecurrent IDHwt Gliomas With FGFR1-TACC1 Fusion, Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion

Start: 2015-09-30End: 2018-10-31Updated: 2019-05-29

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Abbisko Therapeutics Co, LtdUrothelial Carcinoma

Start: 2021-06-03End: 2024-05-27Target: 108Updated: 2021-10-21

Phase 2

Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer

TerminatedNCT01457846

AstraZenecaGastric Cancer, Gastro-oesophageal Junction Cancer

Start: 2011-11-30End: 2015-02-28Updated: 2017-03-07

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

CompletedNCT02117167

UNICANCERNon-small Cell Lung Cancer Metastatic

Start: 2014-04-23End: 2023-12-31Updated: 2024-01-10

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruitingNCT02299999

UNICANCERMetastatic Breast Cancer

Start: 2014-04-07End: 2025-12-31Updated: 2025-01-15

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Active, not recruitingNCT02664935

University of BirminghamAdenocarcinoma, Carcinoma, Squamous Cell, Non-Small Cell Lung Cancer

Start: 2015-05-31End: 2025-09-30Updated: 2025-05-21

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Abbisko Therapeutics Co, LtdUrothelial Carcinoma

Start: 2022-09-30End: 2025-12-30Target: 80Updated: 2023-03-20

Related Papers

Mapping the rapid growth of multi-omics in tumor immunotherapy: Bibliometric evidence of technology convergence and paradigm shifts

Human Vaccines & Immunotherapeutics2025-04-243 citations

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.

2025-03-114 citations

Efficacy and safety of fexagratinib (Fexa) in combination with tislelizumab (T) in a phase II study of patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) harboring FGFR alterations (FGFRa).

Journal of Clinical Oncology2025-02-101 citations

Efficacy and safety of fexagratinib (Fexa) in Chinese patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) harboring FGF receptor (FGFR) genetic alterations.

Journal of Clinical Oncology2025-02-10

Genomic instability in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/ IFCT1301 trial.

Journal of Clinical Oncology2024-06-011 citations

251P Genomic alterations of breast cancer patients with leptomeningeal disease: A retrospective analysis

ESMO Open2024-05-011 citations

TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma

Neuro-Oncology Advances2024-01-019 citations

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Journal of Clinical Investigation2023-11-0736 citations

CTNI-33. TARGET TRIAL: A PHASE I/II OPEN-LABEL MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFICACY OF AZD4547 IN PATIENTS WITH RELAPSED/REFRACTORY FGFR FUSION POSITIVE GLIOMA

Neuro-Oncology2023-11-013 citations

Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.

Journal of Clinical Oncology2023-06-011 citations

Genomics to select treatment for patients with metastatic breast cancer.

2022-09-07119 citations

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Nature Communications2022-06-1065 citations

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).

2021-05-2445 citations

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

Genome Medicine2021-05-1853 citations

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.

2021-05-0384 citations

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.

2020-01-24221 citations

Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation

Cancer Research2019-07-012 citations

Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation

Clinical Research (Excluding Clinical Trials)2019-07-01

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.

2019-05-2938 citations

An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.

Journal of Clinical Oncology2018-05-205 citations

10 more papers not shown